|
| Press Releases |
|
 |
|
| Thursday, July 18, 2019 |
|
|
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019 |
| Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation. more info >> |
|
|
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019 |
| Eisai Co.,Ltd. announced its latest data of nonclinical research which examined the effect to the synaptic function in the brain by spinal densities in regard to oral BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitor elenbecestat were presented at AAIC. more info >> |
|
| Wednesday, July 17, 2019 |
|
|
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China |
| Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration (NMPA). more info >> |
|
| Thursday, July 11, 2019 |
|
|
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002. more info >> |
|
|
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019 |
| Eisai Co., Ltd. announced today that a total of 13 presentations containing two oral presentations including the latest data of the anti-amyloid beta (A beta) protofibril antibody BAN2401 and the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat, will be given at the Alzheimer's Association International Conference (AAIC) 2019.. more info >> |
|
| Wednesday, July 10, 2019 |
|
|
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts |
| Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities. more info >> |
|
| Monday, July 8, 2019 |
|
|
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery |
| Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area. more info >> |
|
| Tuesday, June 18, 2019 |
|
|
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130 |
| Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi's group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin. more info >> |
|
|
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand. more info >> |
|
| Wednesday, May 29, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting |
| Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleepwake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 2, 2026 22:00 HKT/SGT
|
|
|
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor
Feb 2, 2026 20:30 HKT/SGT
|
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb 2, 2026 20:00 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 2, 2026 16:29 JST
|
|
|
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 2, 2026 14:30 JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 13:29 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 13:17 HKT/SGT
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials 
Feb 2, 2026 08:00 HKT/SGT
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 17:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00 HKT/SGT
|
|
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT/SGT
|
|
|
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 21:30 HKT/SGT
|
|
|
SuperX Commences Production at First Global Supply Center
Jan 30, 2026 19:24 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
